AM1241 (0.1-3 mg/kg, i.p.) dose-dependently inhibits sensory hypersensitivity in rats. AM1241 inhibits tactile hypersensitivity and thermal hypersensitivity at 1 mg/kg and 3 mg/kg, respectively, in mice lacking the CB1 receptor[1]. AM1241 (0.75, 1.5, 3, 6, 12 mg/kg, i.p.) alleviates MPTP-induced Parkinson's disease and promotes the regeneration of dopaminergic (DA) neurons in PD mice[2].
In Vitro
AM1241 is a potent and selective CB2 receptor agonist, with a Ki of 3.4 nM in a mouse spleen, and the Ki for CB1 receptor in rat brain is 280 nM, 82-fold selectivity for the CB2 receptor in rodent tissue[1]. AM1241 decreases oxidative stress levels, enhances the production of paracrine growth factors, decreases TGF-β1 and PDGF levels, activates Stat3 via the phosphorylation of Akt and Erk1/2[3].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Ibrahim MM, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10529-33.
[2]. Shi J, et al. AM1241 alleviates MPTP-induced Parkinson's disease and promotes the regeneration of DA neurons in PD mice. Oncotarget. 2017 Jun 29;8(40):67837-67850.
[3]. Han D, et al. Activation of cannabinoid receptor type II by AM1241 protects adipose-derived mesenchymal stem cells from oxidative damage and enhances their therapeutic efficacy in myocardial infarction mice via Stat3 activation. Oncotarget. 2017 May 4;8(39):64853-64866.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
